Evidence map›Paper›PMID 42100144›Full record

ArticleMolecular therapy. Oncology2026

Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas.

Konstantinos Vazaios, Antonio C Tallon-Cobos, Louisa P J van Oosterhout, Piotr Waranecki, Annelisa M Cornel, Noël M M Dautzenberg, Marliek van Hoesel, Caitlyn Forbes, Stefan Nierkens, Vera Kemp and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Konstantinos VazaiosPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Antonio C Tallon-CobosPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Louisa P J van OosterhoutPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Piotr WaraneckiPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Annelisa M CornelPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Noël M M DautzenbergPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Marliek van HoeselPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Caitlyn ForbesPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Stefan NierkensPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Vera KempDepartment of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, the Netherlands.
Rob C HoebenDepartment of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, the Netherlands.
Jasper van der LugtPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Friso G CalkoenPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.
Esther HullemanPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the success of CAR (chimeric antigen receptor) T cells in hematological malignancies, their effectiveness against solid or brain tumors, such as pediatric diffuse midline gliomas (DMGs), is limited. CAR T cell success is hampered by factors including immunosuppression from DMGs and their surrounding tumor microenvironment (TME). Oncolytic viruses (OVs) can reverse this immunosuppression, suggesting a potential combination with CAR T cells. Here, we show that infection with Goravir adenovirus and R124 reovirus induced DMG cell lysis (

Indexed as

B7H3CAR T-cell therapydiffuse midline gliomaGD2Goravirimmune-oncologyimmunotherapyMT: Special Issue - Advancements in pediatric cancer therapyoncolytic viral therapypediatricR124

Identifiers

PMID42100144
PMCPMC13145386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.